| Dr Corey L Martin, MD | |
|
1700 Highway 25 N, Buffalo, MN 55313-1930 | |
| (763) 682-1313 | |
| Not Available |
| Full Name | Dr Corey L Martin |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 1700 Highway 25 N, Buffalo, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447272760 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 47979 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centracare Health - Monticello | Monticello, MN | Hospital |
| Buffalo Hospital | Buffalo, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stellis Health Pa | 1153233796 | 56 |
News Archive
The University of Sydney's Driver Rehabilitation Clinic is seeking participants for the trial of a new specialised driver training program that aims to assist young people with Asperger Syndrome (AS) to learn to drive safely.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.
Ten years ago, Grant Lipman, MD, an emergency medicine physician, was working as a doctor for endurance athletes who were running 25 to 50 miles a day in various parts of the world, from China to Antarctica to Chile.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.
› Verified 9 days ago
| Entity Name | Stellis Health Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184664674 PECOS PAC ID: 1153233796 Enrollment ID: O20031103000458 |
News Archive
The University of Sydney's Driver Rehabilitation Clinic is seeking participants for the trial of a new specialised driver training program that aims to assist young people with Asperger Syndrome (AS) to learn to drive safely.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.
Ten years ago, Grant Lipman, MD, an emergency medicine physician, was working as a doctor for endurance athletes who were running 25 to 50 miles a day in various parts of the world, from China to Antarctica to Chile.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.
› Verified 9 days ago
| Entity Name | Grand Itasca Clinic And Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669426631 PECOS PAC ID: 8123939550 Enrollment ID: O20031105000209 |
News Archive
The University of Sydney's Driver Rehabilitation Clinic is seeking participants for the trial of a new specialised driver training program that aims to assist young people with Asperger Syndrome (AS) to learn to drive safely.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.
Ten years ago, Grant Lipman, MD, an emergency medicine physician, was working as a doctor for endurance athletes who were running 25 to 50 miles a day in various parts of the world, from China to Antarctica to Chile.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.
› Verified 9 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
The University of Sydney's Driver Rehabilitation Clinic is seeking participants for the trial of a new specialised driver training program that aims to assist young people with Asperger Syndrome (AS) to learn to drive safely.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.
Ten years ago, Grant Lipman, MD, an emergency medicine physician, was working as a doctor for endurance athletes who were running 25 to 50 miles a day in various parts of the world, from China to Antarctica to Chile.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.
› Verified 9 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1275872772 PECOS PAC ID: 3870739410 Enrollment ID: O20130426000215 |
News Archive
The University of Sydney's Driver Rehabilitation Clinic is seeking participants for the trial of a new specialised driver training program that aims to assist young people with Asperger Syndrome (AS) to learn to drive safely.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.
Ten years ago, Grant Lipman, MD, an emergency medicine physician, was working as a doctor for endurance athletes who were running 25 to 50 miles a day in various parts of the world, from China to Antarctica to Chile.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Corey L Martin, MD 1700 Highway 25 N, Buffalo, MN 55313-1930 Ph: (763) 682-1313 | Dr Corey L Martin, MD 1700 Highway 25 N, Buffalo, MN 55313-1930 Ph: (763) 682-1313 |
News Archive
The University of Sydney's Driver Rehabilitation Clinic is seeking participants for the trial of a new specialised driver training program that aims to assist young people with Asperger Syndrome (AS) to learn to drive safely.
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.
Ten years ago, Grant Lipman, MD, an emergency medicine physician, was working as a doctor for endurance athletes who were running 25 to 50 miles a day in various parts of the world, from China to Antarctica to Chile.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.
› Verified 9 days ago
Dr. Kelly Gail Kinnan, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1700 Highway 25 N, Buffalo, MN 55313 Phone: 763-682-1313 | |
Emily Lawrence, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Highway 25 N, Buffalo, MN 55313 Phone: 763-682-1313 | |
Asitha Dias, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 303 Catlin St, Buffalo, MN 55313 Phone: 763-682-5225 | |
Dr. Michael J Smith, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1700 Highway 25 N, Buffalo, MN 55313 Phone: 763-682-1313 | |
Dr. Franklin O. Anderson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Highway 25 N, Buffalo Clinic, Buffalo, MN 55313 Phone: 763-682-1313 | |
Dr. Ronald Duane Brown, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1630 Anderson Ave, Whitesell Medical Staffing, Buffalo, MN 55313 Phone: 763-682-5906 Fax: 763-684-0243 | |
Natasha A Hamann, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 303 Catlin St, Buffalo, MN 55313 Phone: 763-682-5225 Fax: 763-684-6111 |